Actavis Confirms District Court Ruling In Generic Rapamune Patent Suit

Thu Jan 31, 2013 4:05pm EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link

PARSIPPANY, N.J., Jan. 31, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today
confirmed that the United States District Court for the District of  Delaware 
has found United States Patent No. 5,100,899 (the '899 Patent) valid and
infringed by Actavis' generic version of Pfizer Inc.'s Rapamune (sirolimus). 
The Company said that it was reviewing the court's decision and would evaluate
all available options, including an appeal.  

Rapamune tablets are indicated for the prophylaxis of organ rejection in
patients aged 13 years or older receiving renal transplants.  Actavis'
Abbreviated New Drug Application ("ANDA") for its generic version of Rapamune
has not yet received tentative or final approval from the U.S. Food and Drug

About Actavis

Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical
company focused on developing, manufacturing and distributing generic, brand and
biosimilar products.  The Company has global and U.S. headquarters in 
Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland.

Actavis is the world's third-largest generics prescription drug manufacturer. 
Operating as Actavis Pharma, the Company develops, manufactures and markets
generic, branded generic, legacy brands and Over-the-Counter (OTC) products in
more than 60 countries.  The Company is ranked in the top 3 in 12 global
markets, the top 5 in 16 global markets, and in the top 10 in 33 global markets.
 Actavis Pharma also develops and out-licenses generic pharmaceutical products
outside the U.S. through its Medis third-party business, the world's largest
generic pharmaceutical out-licensing business. Medis has more than 300 customers
globally, and offers a broad portfolio of more than 200 products.   

Actavis Specialty Brands is the Company's global branded specialty
pharmaceutical business, which develops and markets a portfolio of approximately
40 products principally in  the United States  and  Canada  that are focused in
the Urology and Women's Health therapeutic categories.  Actavis Specialty Brands
is committed to developing and marketing biosimilars products in Women's Health,
Oncology and other therapeutic categories, and currently has a portfolio of 5
biosimilar products in development.  

Actavis Global Operations has more than 30 manufacturing and distribution
facilities around the world, with a capacity of approximately 44 billion units
annually.  Actavis Global Operations also includes Anda, Inc., the
fourth-largest U.S. generic pharmaceutical product distributor in  the United

For press release and other company information, visit Actavis' Web site at

Forward-Looking Statement  

Statements contained in this press release that refer to non-historical facts
are forward-looking statements that reflect Actavis' current perspective of
existing information as of the date of this release.  It is important to note
that Actavis' goals and expectations are not predictions of actual performance.
Actual results may differ materially from Actavis' current expectations
depending upon a number of factors, risks and uncertainties affecting Actavis'
business. These factors include, among others; the difficulty of predicting the
timing and outcome of any appeal of the pending patent litigation; the
difficulty of predicting the timing or outcome of product development efforts,
including FDA and other regulatory agency approvals and actions, if any; the
impact of competitive products and pricing; the timing and success of product
launches; difficulties or delays in manufacturing; the availability and pricing
of third party sourced products and materials; successful compliance with FDA
and other governmental regulations applicable to Actavis and its third party
manufacturers' facilities, products and/or businesses; changes in the laws and
regulations; and such other risks and uncertainties detailed in Actavis'
periodic public filings with the Securities and Exchange Commission, including
but not limited to Actavis' Annual Report on form 10-K for the year ended 
December 31, 2011  and its Quarterly Report on Form 10-Q for the period ended 
September 30, 2012  (such periodic public filings having been filed under the
"Watson Pharmaceuticals, Inc." name).  Except as expressly required by law,
Actavis disclaims any intent or obligation to update these forward-looking

Rapamune®  is a registered trademark of Pfizer Inc.

 CONTACTS:  Investors:        
            Lisa DeFrancesco  
            (862) 261-7152    
            Charlie Mayr      
            (862) 261-8030    

(Logo:  )

SOURCE  Actavis, Inc.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.